For August 2025, the editors of AACR's journals highlighted studies on liquid biopsy for brain cancer, new treatment strategies for prostate and colorectal cancers, and more.
A chemotherapy-releasing device helps destroy bladder cancer tumors, and long-distance running linked to increased risk for precancerous polyps.
A new study suggests steroids could blunt the effects of some immunotherapies, but researchers say they remain necessary for some patients.
Researchers highlighted AI's potential to enhance clinical cancer care, including to improve diagnosis, guide precision medicine, and more.
Some women over 70 may not need chemotherapy for high-risk breast cancer, and an early trial finds a pancreatic cancer vaccine can trigger an immune response.
New clinical trials are exploring an array of CAR T-cell approaches for children with cancers of the brain and spinal cord.
Preliminary results found that combining relacorilant with nab-paclitaxel improved outcomes for women with advanced ovarian cancer.
The FDA has approved zongertinib for patients with unresectable or metastatic non-squamous non-small cell lung cancer that has HER2 tyrosine kinase domain mutations and has undergone prior treatment. The U.S. Food and Drug Administration...
The FDA has approved the first-in-class therapeutic dordaviprone for certain adult and pediatric patients with H3 K27M-mutated diffuse midline glioma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to dordaviprone (Modeyso)...
The AACR hosted a Virtual Patient Advocate Forum in July 2025 on technology’s role in cancer care.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More